Activity of Indatuximab Ravtansine Against Triple-Negative Breast Cancer in Preclinical Tumor Models

Pharmaceutical Research - United States
doi 10.1007/s11095-018-2400-y
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Wee1 Inhibition Enhances the Anti-Tumor Effects of Capecitabine in Preclinical Models of Triple-Negative Breast Cancer

Cancers
Cancer ResearchOncology
2020English

Characterization of Triple-Negative Breast Cancer Preclinical Models Provides Functional Evidence of Metastatic Progression

International Journal of Cancer
Cancer ResearchOncology
2019English

Triple-Negative Breast Cancer

2018English

Cytotoxicity of Selenium Immunoconjugates Against Triple Negative Breast Cancer Cells

International Journal of Molecular Sciences
Organic ChemistryMolecular BiologyTheoretical ChemistryInorganic ChemistryComputer Science ApplicationsSpectroscopyMedicineCatalysisPhysical
2018English

Triple Negative Breast Cancer: Breast Cancer Research in Evolution

Breast Disease
MedicineCancer ResearchOncology
2011English

Tumor Tissue microRNA Expression in Association With Triple-Negative Breast Cancer Outcomes

Breast Cancer Research and Treatment
Cancer ResearchOncology
2015English

Serum Amyloid a Predisposes Inflammatory Tumor Microenvironment in Triple Negative Breast Cancer

Oncotarget
Oncology
2019English

Targeting the Vulnerability of RB Tumor Suppressor Loss in Triple-Negative Breast Cancer

Cell Reports
BiochemistryGeneticsMolecular Biology
2018English

HMGA1: A Master Regulator of Tumor Progression in Triple-Negative Breast Cancer Cells

PLoS ONE
Multidisciplinary
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy